Paul, Weiss is advising Metsera, a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and cardiometabolic diseases, in its sale to Pfizer. Under the terms of the agreement, Pfizer will acquire all outstanding shares of Metsera common stock for $47.50 per share in cash at closing, representing an enterprise value of approximately $4.9 billion. The deal also includes a non-transferable contingent value right (CVR) entitling holders to potential additional payments of up to $22.50 per share in cash tied to specific clinical and regulatory milestones, for a total deal value of up to $8.1 billion.
The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
The Paul, Weiss team is led by Corporate Partners Benjamin Goodchild, Andrew Krause and Scott Barshay, and includes Partner Patricia Vaz de Almeida; Executive Compensation Partner Matthew Friestedt and Counsel Cynthia Akard; Tax Partners Anne McGinnis and Brian Krause; Intellectual Property Partners Jonathan Ashtor and Jeffrey Osterman, and Counsel Matthew Rosenberg; and Antitrust Partners Scott Sher and Nicole Kar.
Wachtell, Lipton, Rosen & Katz is serving as legal counsel to Pfizer.
The deal reporting on this platform is based on the information received from law firms, and therefore, some details may be missing/incomplete. If your firm has not been credited for this deal, write to us at chanchal.makhija@thegreymatter.co.in mentioning your firm’s name, lawyers involved (including designation) and client represented.
